The effects of galanin-like peptide on energy balance, body temperature and brain activity in the mouse and rat are independent of the GALR2/3 receptor.
Galanin-like peptide (GALP) is a neuropeptide that is thought to act on the galanin receptors GALR1, GALR2 and GALR3. In rats, i.c.v. injection of GALP has dichotomous actions on energy balance, stimulating feeding over the first hour, but reducing food intake and body weight at 24 h, as well as causing an increase in core body temperature. In mice, GALP only induces an anorexic action, and its effects on core body temperature are unknown. One aim of the present study was to determine the effects of GALP on core body temperature in mice. Intracerebroventricular injection of GALP into conscious mice had no effect on feeding over 1 h, but caused a significant reduction in food intake and body weight at 24 h. It also caused an immediate drop in core body temperature, which was followed by an increase in body temperature. To understand these different effects of GALP on energy balance in mice compared to rats, and to determine the involvement of GALR2 and GALR3, immunohistochemistry was performed to localise c-Fos, a marker of cell activation. Intracerebroventricular injection of GALP induced c-Fos expression in the parenchyma surrounding the ventricles, the ventricular ependymal cells and the meninges in mice and rats. GALP also induced c-Fos expression in the supraoptic nucleus, dorsomedial hypothalamic nucleus, lateral hypothalamus and nucleus tractus solitarius in rats but not in mice. Central administration of a GALR2/3 agonist in rats did not induce c-Fos in any of the brain regions that expressed this protein after GALP injection, and had no effect on food intake, body weight and body temperature in rats or mice. These data suggest that GALP induces differential effects on energy balance and brain activity in mice compared to rats, which are unlikely to be due to activation of the GALR2 or GALR3 receptor.
Man
P-S
PS
Faculty of Life Sciences, University of Manchester, Manchester, UK.
Lawrence
C B
CB
D000818:Animals; D000831:Animals, Newborn; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D002478:Cells, Cultured; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects*; D019004:Galanin / Q000008:administration & dosage / Q000494:pharmacology; D044089:Galanin-Like Peptide / Q000008:administration & dosage / Q000494:pharmacology*; D006706:Homeostasis / Q000187:drug effects; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044092:Receptor, Galanin, Type 2 / Q000819:agonists / Q000502:physiology*; D044093:Receptor, Galanin, Type 3 / Q000819:agonists / Q000502:physiology*
D044089:Galanin-Like Peptide; D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; D044092:Receptor, Galanin, Type 2; D044093:Receptor, Galanin, Type 3; C434734:galanin (2-11)-amide; D019004:Galanin